Drug Trial Radar · NCT06716879
A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of a Single Dose of Donzakimig in Healthy Chinese and Japanese Participants
Last checked: Nov 19, 2026Latest source record: Feb 18, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
32
Actual
Start
Dec 6, 2024
Primary completion
Apr 4, 2025
Study completion Apr 4, 2025
Sponsor
- Lead sponsor
- UCB Biopharma SRLUCB
- Sponsor type
- Industry
- First posted
- Dec 4, 2024
Design
- Study type
- Interventional
- Phase
- Phase 1
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Basic science
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 55 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to investigate the safety, tolerability, and pharmacokinetic parameters of 2 dose strengths of donzakimig, each administered subcutaneously as a single dose, in healthy Chinese and Japanese study participants.
Conditions
- Healthy Participants
Interventions
DonzakimigDrug
Drug: Donzakimig Pharmaceutical form: Subcutaneous solution
PlaceboDrug
Drug: Placebo Pharmaceutical form: Subcutaneous solution
Primary outcomes
What the sponsor says the trial is designed to measure.
- Occurrence of treatment-emergent adverse events (TEAEs)Time frame: From Baseline to End of Study visit (up to Day 57)
- Occurrence of serious treatment-emergent adverse events (serious TEAEs)Time frame: From Baseline to End of Study visit (up to Day 57)
- Maximum plasma concentration (Cmax) of donzakimigTime frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.
- Area under the plasma concentration-time curve from time 0 to t of donzakimigTime frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.
- Area under the plasma concentration-time curve from zero to infinity of donzakimigTime frame: Sampling timepoints will be on Day 1 (D1): at predose and 6 hours (h), 24h (D2), 72h (D4), 120h (D6), D8, D15, D22, D36, and D57 after investigational medicinal product (IMP) administration.
Locations
1 site in 1 country. Site status is shown where the registry gives one.
UP0142 1
Anaheim, California
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.